Dr. Allyson Berent graduated from Cornell University College of Veterinary Medicine in 2002. She completed an internship at the University of Minnesota and a residency in internal medicine at the Veterinary Hospital of the University of Pennsylvania, thereafter. She was boarded in internal medicine in 2006. After completing a fellowship in interventional radiology at the Veterinary Hospital of the University of Pennsylvania and a fellowship in Endourology at Thomas Jefferson University she served as a Adjunct Assistant Professor in Internal Medicine and Interventional Radiology/ Interventional Endoscopy at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania. Since 2009, she holds a staff position at the Animal Medical Center in Interventional Radiology and Endoscopy and is director of the Interventional Endoscopy Services. In 2015 Dr. Berent became the Chief Science Officer for the Foundation for Angelman Syndrome Therapeutics and has been integral in driving the research portfolio in novel treatment options for this rare genetic disorder. In 2017 Dr. Berent became the Chief Operating Officer of GeneTx Biotherapeutics, a company with a sole mission to advance antisense oligonucleotide therapies toward human clinical trials for the treatment of Angelman syndrome. In 2022 GeneTx Biotherapeutics was acquired by Ultragenyx.